David Ring, DO
Family Medicine · Pryor, OKNPI 1871516898
Payments from drug & device makers
Across 170 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$557
- AstraZeneca$314
- Sanofi-aventis U.S. LLC$307
- Lilly USA, LLC$211
- GSK$158
- Pfizer$129
- plus $934 from 19 others
What the payments were for
- Food & beverage$2,604100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $557 |
| AstraZeneca | 15 | $314 |
| Sanofi-aventis U.S. LLC | 22 | $307 |
| Lilly USA, LLC | 14 | $211 |
| GSK | 11 | $158 |
| Pfizer | 9 | $129 |
| Merck | 9 | $119 |
| Amgen | 8 | $106 |
| Kowa Pharmaceuticals America, Inc. | 6 | $84 |
| Boehringer Ingelheim | 6 | $83 |
| Novartis | 4 | $67 |
| Amarin Pharma, Inc. | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Abbott | 2 | $42 |
| Exact Sciences | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| AbbVie | 2 | $38 |
| Johnson & Johnson | 3 | $37 |
| Bayer | 2 | $32 |
| Mylan Specialty L.p. | 2 | $32 |
| Astellas Pharma US Inc | 2 | $28 |
| Dexcom, Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,610 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 92 | $114,001 |
| EliquisApixaban | 109 | $80,090 |
| OzempicSemaglutide | 80 | $77,098 |
| FarxigaDapagliflozin Propanediol | 103 | $74,011 |
| JardianceEmpagliflozin | 71 | $71,832 |
| TrulicityDulaglutide | 64 | $67,652 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $39,313 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $38,509 |
| XareltoRivaroxaban | 59 | $37,429 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $35,821 |
| LinzessLinaclotide | 52 | $35,115 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $30,053 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $24,140 |
| TradjentaLinagliptin | 21 | $18,092 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 27 | $17,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $211 | $181,652156 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Spiriva Respimat, Combivent Respimat | $83 | $133,055170 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $314 | $104,041149 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Shingrix | $158 | $91,671168 claims |
| PfizerEliquis, Premarin | $129 | $88,506138 claims |
| Novo NordiskOzempic | $557 | $77,09880 claims |
| Johnson & JohnsonXarelto | $37 | $37,42959 claims |
| AbbVieLinzess | $38 | $35,11552 claims |
| MerckJanuvia, Belsomra | $119 | $22,33838 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $307 | $15,85318 claims |
| BayerKerendia | $32 | $6,87411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Pryor
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.